Ann: Quarterly Activities Report & Appendix 4C, page-2

12.3m cash and 1.9m expected expenditure for next q, great potential, it's a waiting game till the figures from the initial revenues come in 3 months time from now:

"The Chinese health food market – which includes vitamins, dietary supplements and minerals, animal and herbal extracts and traditional Chinese medicine – is currently valued at RMB200 billion
(US$31 billion; A$39 billion) and is projected to grow by 10 per cent every year between now and 2025
Creso is also in advanced discussions with other Asian pharmaceutical and cosmetic groups. This will open up the path to bring Creso’s products and IP to Asia in a fast, effective and efficient manner so the Company can reach a massive population of consumers and patients."

And don't stress:

"Creso is very conscious of its legal obligations in all jurisdictions and will only ever distribute products in compliance with local laws."

"Creso expects to achieve a number of key milestones over the coming months, namely the Swiss launch of cannaQIX®10 and the UK launch of the cannaQIX®10 and 50 products, which will bring the first revenues for the Company’s human health product line.
It also expects to import of cannaQIX®50 into Australia, via its commercial partner, Health House, in the second half of 2018, cementing its competitive advantage in the local market.
The Company also plans to continue securing commercial agreements for both the cannaQIX® range as well as the anibidiol® animal health range of products, after the launch of the latter in Switzerland during the December quarter.
At the same time, the Company will continue to expand its global presence through commercial agreements and acquisitions. It expects to provide investors with updates on the Kunna acquisition and the Mernova acquisition in Canada over the coming weeks."